Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Open Access
- 18 September 2019
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 55 (2) , 356-366
Abstract
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventional registry study (NCT01362972), evaluated long-term outcomes for MM patients who received plerixafor versus other mobilization regimens. The comparisons were: G-CSF + plerixafor (G-CSF + P) versus G-CSF-; G-CSF + P versus G-CSF + chemotherapy (G-CSF + C); and G-CSF + P + C versus G-CSF + C. Propensity score matching was used to balance groups. Primary outcome measures were progression free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR) after transplantation. After propensity matching, 77 versus 41 patients in the G-CSF + P versus G-CSF cohorts, 129 versus 129 in the G-CSF + P versus G-CSF + C cohorts, and 117 versus 117 in the G-CSF + P + C versus G-CSF + C cohorts were matched, respectively. Propensity score matching resulted in a smaller sample size and imbalances were not completely overcome. For both PFS and OS, the upper limits of the hazard ratio 95% confidence intervals exceeded prespecified boundaries; noninferiority was not demonstrated. CIR rates were higher in the plerixafor cohorts. G-CSF + P remains an option for the mobilization of HSCs in poor mobilizers with MM with no substantial differences in PFS, OS, and CIR in comparison with other regimens.Keywords
Funding Information
- Sanofi
This publication has 29 references indexed in Scilit:
- Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2015
- Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantationBone Marrow Transplantation, 2015
- Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single‐centre experienceVox Sanguinis, 2014
- Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization.Cytotherapy, 2012
- Evaluation of the Propensity score methods for estimating marginal odds ratios in case of small sample sizeBMC Medical Research Methodology, 2012
- PlerixaforNature Reviews Drug Discovery, 2009
- Cytokines and hematopoietic stem cell mobilizationJournal of Cellular Biochemistry, 2006
- How do stem cells find their way home?Blood, 2005
- New Strategies for Mobilization of Hematopoietic Stem CellsFuture Oncology, 2005
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958